MED19 and melanoma: Interestingly, four (MED12, MED16, MED19, and MED23) out of six of the mediator complex subunits found to be significantly enriched in our study were also enriched in the GeCKO screen performed by Shalem et al, who screened for verumafenib resistance (BRAF V600E inhibitor) in melanoma.3